DOCSLIB.ORG

Announcements

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Announcements Announcements PRELIMINARY ANNOUNCEMENT OF THE ELEVENTH INTERNATIONAL CANCER CONGRESS The Eleventh International Cancer Congress organized under the auspices of the International Union Against Cancer (UICC) will be centered in Florence, Italy, October 20—26, 1974. Following the Opening Ceremony at the Palazzo Vecchio, the first 2 days will be devoted to special sessions in Florence and in nearby towns, organized mainly on a unidisciplinary basis. The regular sessions will be held in Florence. The program comprises multidisciplinary symposia in the mornings, and workshops or presentations of papers in the afternoons. Scientific films and displays are planned. A Memorial Lecture will be delivered at the Closing Ceremony, and advanced courses in clinical oncology are scheduled to follow the Congress, on October 28—29.French, English, and Italian will be the official languages, with simultaneous interpretation at most sessions. Forms for registration and hotel accommodations, as well as information on travel, tours, and special events, will be provided in the Second Circular to be issued in October 1972. Further information and copies of Circular 2 will be available from the Secretary General, Dr. Umberto Veronesi, Eleventh International Cancer Congress, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via G. Venezian 1, 20133 Milan, Italy. GYNECOLOGIC ONCOLOGY GROUP The Gynecologic Oncology Group has been organized by gynecologists, medical oncologists, radiation therapists, and related specialists interested in neoplasms originating in the female genital system. It is hoped that the coordination and cooperation among individuals representing these specialities in preparing, conducting, and evaluating appropriate investigation will result in improved care to their patients. Protocols intended to determine optimal therapy in a number of clinical situations have been adopted. The Gynecologic Oncology Group will consider studying the wide range of problems relating to the diagnosis, management, and biology of these cancers. The Group is supported by the National Cancer Institute. Institutions interested in participation may contact Dr. Myroslaw M. Hreshchyshyn, Chairman, Gynecologic Oncology Group, Operations Office, Buffalo General Hospital, 100 High Street, Buffalo, New York 14203 (Telephone: 716-845-6554 or 716-845-6414). BRIEF COMMUNICATIONS FOR THE JOURNAL OF THE NATIONAL CANCER INSTITUTE In the interest of disseminating information more rapidly, the Editors of the Journal of the National Cancer Institute solicit Brief Communications for publication. Every effort will be made to expedite review and inclusion in the Journal so that such manuscripts will reach the reader in approximately 16 weeks. A Brief Communication should not supplant a more thoroughly documented study, but may precede it as an indicator of ongoing investigations. The following criteria will be used for selection of manuscripts as Brief Communications: 1. The subject must be timely and of a nature and substance that permits other investigators to utilize the information. 2. The manuscript must be no longer than 8 full, double-spaced typewritten pages, including title, signature with complete mailing address, brief summary, text, tables, and references. 3. One additional page may be devoted to text figures or plates, but such inclusions may delay publication. 4. Avoid subheadings, footnotes, prolonged introductory comments, and speculative discussion. Limit references to essential works that are completely indexed. 2196 CANCER RESEARCH VOL. 31 Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1971 American Association for Cancer Research. Announcements 5. Submit manuscripts in the format for regular manuscripts described on the back cover of each issue of the Journal of the National Cancer Institute. TRAINEESHIPS St. Jude Children's Research Hospital, Memphis, Tennessee, offers opportunities for research and clinical training in cancer to physicians and scientists. Traineeships are available in biochemistry, virology, immunology, pharmacology, pathology, hematology, oncology, cancer chemotherapy, radiology, infectious diseases, and nutrition. For further information, write to Dr. Donald Pinkel, Medical Director, St. Jude Children's Research Hospital, P. 0. Box 318, Memphis, Tennessee 38101. ONCOLOGY FELLOWSHIPS Applications are now being accepted for Clinical Research Fellowships in Oncology and Cancer Chemotherapy at the University of Southern California School of Medicine. The fellowships are of one or two years' duration, beginning July 1, 1972. Fellows have broad patient responsibility and supervise two residents and two interns. If desired the fellowship may include a three-month rotation on the Hematology or Radiation Therapy Services. The Fellowship can count toward the proposed subspecialty certification in oncology. The stipend is $14,784 to $17,052, varying with experience. Applicants should have completed two years of training in internal medicine (one year of uninterrupted internship plus one year of residency, or one year of rotating internship plus two years of residency) before starting the fellowship and should be United States citizens, eligible for a California license. A resume should be sent to Dr. David Stolinsky, U. S. C. Oncology Service, 2825 South Hope Street, Los Angeles, California 90007. SECOND CONFERENCE AND WORKSHOP ON EMBRYONIC AND FETAL ANTIGENS IN CANCER A Second Conference and Workshop on Embryonic and Fetal Antigens in Cancer will be held February 14 to 16, 1972. The first conference was held in May 1971, and a monograph containing formal presentation and workshop summaries is in press. The subjects covered in the 1972 symposium and workshop will be: differentiation of eukaryotic cells, detection (immunological and biochemical) of fetal expression in cancer cells and in developing fetus; fetal antigens in human and animal cancer; and mechanisms of retrogenesis in cancer detection. Researchers interested in presenting data or theoretical considerations at the Second Conference should submit a one-page abstract of their offerings no later than December 15, 1971. Notification of manuscript acceptance will be made by December 30, 1971, and the complete program will be announced at that time. Completed manuscripts for publication of invited papers will be due by February 13, 1972. Information concerning lodging arrangements will be sent out at the time of manuscript acceptance. Abstracts should be submitted to Dr. Norman G. Anderson, Director, Molecular Anatomy (MAN) Program, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37830. SIDNEY FARBER MEDICAL RESEARCH AWARD The Sidney Farber Medical Research Award for 1971 was presented to Senator Lister Hill. The Award was established by those professional colleagues associated with the Children's Cancer Research Foundation during its first twenty years and is in appreciation of Dr. Farber's contributions to medicine and to the development and support of medical care and medical research in this country and abroad. Senator Hill, past chairman of the Labor and Public Welfare Committee of the Senate and of the Senate Appropriations Subcommittee on Labor-Health, Education and Welfare, has been concerned with translating the health needs of the country into effective legislation, encouraging the creation of hospitals, the Hill-Burton Act, and the building of medical research facilities, such as the National Library of Medicine and the National Institutes of Health. DECEMBER 1971 2197 Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1971 American Association for Cancer Research. Announcements Cancer Res 1971;31:2196-2197. Updated version Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/31/12/2196.citation E-mail alerts Sign up to receive free email-alerts related to this article or journal. Reprints and To order reprints of this article or to subscribe to the journal, contact the AACR Publications Subscriptions Department at [email protected]. Permissions To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/31/12/2196.citation. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site. Downloaded from cancerres.aacrjournals.org on September 28, 2021. © 1971 American Association for Cancer Research. .
Load more

Recommended publications
  • Natural Resistance to Methotrexate in Human Melanomas
    0022-202X/80/7504-0357$02.00/0 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY, 75:357-359, 1980 Vol. 75, No. 4 Copyright © 1980 by The Williams & Wilkins Co. Printed in U.S.A. Natural Resistance to Methotrexate in Human Melanomas DONALD W. KUFE, M .D ., MICHAEL M. WICK, M .D., PH.D., AND HERBERT T. ABELSON, M.D. Divisions of Pharmacology and Medical Onco logy (DWK and MM-w,J Sidney Farber Cancer Institute; Division of Pediatric Oncology (HTA) Sidney Farber Cancer Institute; and Departments of Medicine (DWK), Dermatology (MM"I¥,) and Pediatrics (HTA) Harvard Medical School, Boston, Massachusetts, U.S.A. Human melanomas are naturally resistant to metho­ resistant to the effects of MTX in vitro. The intracellular trexate (MTX). The mechanism of intrinsic drug resist­ uptake of MTX in these lines is comparable to other human ance has been explored in 3 melanoma cell lines not tumor cell lines. The mechanism of MTX resistance is attrib­ previously exposed to this agent. All 3 lines exhibited uted to elevated endogenous levels of DHFR. relative MTX resistance with ID5o values of greater than 1 fLM. Drug uptake studies were performed over an extra­ MATERIALS AND METHODS cellular concentration range of 0.1 to 10 ILM MTX. The Melanoma Growth Studies uptake was linear over the initial 10 min at all concen­ The growth characteristics of melanoma cell lines have been previ­ trations and subsequently reached plateau levels only at ously described [15]. Each line was established from metastatic mela­ the 10 ILM concentration. Lineweaver-Burke transfor­ noma and continues to have morphologic characteristics of melanin­ mations yielded apparent Km (uptake) values of 1.4 to 5 producing cells.
    [Show full text]
  • Awards, Appointments, Announcements
    NEWS Frederick W. Alt, Ph.D., a Howard biomedical science at the University of Awards, Hughes Medical Institute investigator at Texas Southwestern Medical Center at the Children’s Hospital of Boston, and Dallas, received the AACR Award for Appointments, the Charles A. Janeway Professor of Outstanding Achievement in Cancer Pediatrics and professor of genetics at Research. The award honors an accom- Announcements Harvard Medical School, received the plished young investigator in the field Vincent T. DeVita Jr., M.D., has 44th AACR-G.H.A. Clowes Memorial who is no more than 40 years old at the been named the Amy and Joseph Perella Award for his major discoveries involv- time the award is conferred. Wang was Professor of Medicine at Yale Univer- ing genomic stability and cancer. recognized for important discoveries sity in recognition of his contributions David Sidransky, M.D., was concerning the biochemical mecha- to cancer research and treatment. honored with the 28th AACR-Richard nisms of apoptosis. Director of Yale Cancer Center from & Hinda Rosenthal Foundation Award Paul Talalay, M.D., John Jacob Abel 1993 to 2003, DeVita currently serves for making a notable contribution to Distinguished Service Professor in the Downloaded from https://academic.oup.com/jnci/article/96/6/433/2606773 by guest on 03 October 2021 as chairman of the Yale Cancer Center improved clinical care in the field of Department of Pharmacology and Advisory Board and is a Yale University cancer. Sidransky is a professor of Molecular Sciences at the Johns Hopkins School of Medicine Professor of otolaryngology, oncology, urology, School of Medicine, was selected to Internal Medicine and Epidemiology genetics, pathology, and cellular and deliver the 9th AACR-DeWitt S.
    [Show full text]
  • Dana-Farber Facts
    2020FACTS Who We Are Dana-Farber Cancer Institute blends leading science and exceptional care into transformative medicine. Founded in Boston in 1947, Dana-Farber is a principal teaching affiliate of Harvard Medical School and federally designated a Comprehensive Cancer Center that develops and disseminates innovative patient therapies and scientific discoveries through- out the world. Since 1948, the Jimmy Fund has raised millions of dollars through thousands of community efforts to advance Dana-Farber’s lifesaving mission. EMPLOYEES Full-time 4,748 Part-time 483 Total 5,231 FACULTY MDs 317 PhDs 129 MD/PhDs 98 Total 544 All data in this publication is from fiscal year 2019. PATIENT CARE Dana-Farber cares for adults and children challenged with cancer, blood disorders, and related diseases. Our world-renowned specialists provide comprehensive and personalized care for each patient and support for their families. Our specialized treatment centers are staffed by teams of experts who work closely together to offer patients the latest therapies and strategies, including access to innovative clinical trials. Infusion Treatments 187,664 Outpatient MD Visits 359,519 New Patients 25,118 Unique Patients 74,084 REGISTERED NURSES Registered Nurses, Nurse Practitioners, Clinical Specialists, and Nurse Scientists 744 PATIENT SERVICES VOLUNTEERS Number of Volunteers 503 Combined Hours of Service 26,210 RESEARCH Dana-Farber remains true to its founder, Sidney Farber, MD, and his vision of a cancer center that is just as dedicated to discoveries in cancer research as it is to delivering expert, compassionate care. Through strategic investment in research, we support scientific leaders and young investigators, develop new therapies, and ensure a spirit of collaboration and innovation.
    [Show full text]
  • Curing Children with Acute Lymphoblastic Leukemia
    Curing Children with Acute Lymphoblastic Leukemia Hyperleukocytosis Pinkel Aur Simone Hustu Borell a Total Therapy Studies I-IV 1962-1967 • Introduce combination chemotherapy with prednisone, vincristine, cyclophosphamide, daunorubicin, cytarabine, mercaptopurine, methotrexate • Began Total Therapy with remission induction; intensification; central-nervous-system (CNS)-directed therapy; continuation (maintenance) therapy • Began cranial irradiation to prevent and treat CNS leukemia Central Nervous System Leukemia • Symptoms include: headache, mental status changes, vision changes, seizures, coma, death • Intracranial hemorrhage Facial Palsy in ALL VIIth nerve Total Therapy V 1967-1968 Total Patients 35 Complete Remission 31 Aur et al. Blood 1971; 37:272-81 Legacy of Donald Pinkel Nothing changed the fate of children with ALL (and St Jude Hospital) like Danny Thomas’s appearance on tonight show with Johnny Carson on June 26, 1972 Quote of Yaddanapudi Ravindranath Neuroimaging Abnormalities After Cranial Irradiation • Brain atrophy • Encephalomalacia • Cerebral lacunes • Dystrophic calcification • Leukoencephalopathy • Necrosis/gliosis Endocrinopathy After Cranial Irradiation Brain tumors after cranial irradiation Meningioma Malignant astrocytoma median onset: 20 years median onset: 8 years Overall Survival of Childhood ALL by Treatment Era at St. Jude 94% ± 1% XV, XVI (n=1050) 2000-2017 84% ± 2% 81% ± 2% XIIIA,XIIIB,XIV (n=465) 1991-1999 XI, XII (n=546) 1984-1991 74% ± 2% X (n=428) 1979-1983 48% ± 2% V-IX (n=825) 1967-1979 21% ± 4% I-IV
    [Show full text]
  • Translating Science Into Survival
    Scientific Report 2018 Scientific Report 2018 www.stjude.org/scientificreport 262 Danny Thomas Place Memphis, TN 38105 Physician Referral Service 866.278.5833 Translating Science General Information 901.595.3300 into Survival Behind the Cover The scientific image on the cover is a fluorescence image of pyramidal neurons in the auditory cortex. The brain can modify the structure and function of neuronal connections in response to sensory experiences. This ability is known as neuroplasticity. Stanislav S. Zakharenko, MD, PhD (Developmental Neurobiology), and his Faculty Editorial Board colleagues are investigating the role of neuroplasticity in the Terrence L. Geiger, MD, PhD Nickhill Bhakta, MD, MPH auditory cortex during learning and how dysfunction in that part of Michael A. Dyer, PhD the brain can cause catastrophic neurologic or psychiatric diseases. Alberto S. Pappo, MD Leslie L. Robison, PhD Carlos Rodriguez-Galindo, MD Stephen W. White, DPhil Stanislav S. Zakharenko, MD, PhD Editoral Direction Angela J. McArthur, PhD, ELS Creative Direction Jerry L. Harris Photography Peter Barta Seth Dixon Ann-Margaret Hedges Jere Parobek Prepared by Departments of Scientific Editing and Biomedical Communications St. Jude Children’s Research Hospital and ALSAC are registered trademarks. ST. JUDE INVESTIGATORS, BACKED BY EXTRAORDINARY RESOURCES AND SUPPORT TEAMS, HAVE THE FREEDOM TO FOCUS ON MAKING BIG DISCOVERIES. OUR CULTURE AND CAMPUS FOSTER THE FREE EXCHANGE OF IDEAS AMONG SCIENTISTS AND CLINICIANS TO PROMOTE CREATIVE, COLLABORATIVE SCIENCE. Privileged communication. Copyright © 2018 St. Jude Children’s Research Hospital. No part of this communication may be cited, reproduced, stored in a retrieval system, or transmitted by electronic or other means without prior written permission of the President and CEO and the appropriate investigator.
    [Show full text]
  • A History of St. Judes Children's Research Hospital (.Pdf)
    British Journal of Haematology, 2003, 120, 1–7 Historical Review F A HISTORY OF ST JUDE CHILDRENAPOS;S RESEARCH HOSPITAL The entertainer Danny Thomas founded St Jude Children’s Cardinal Samuel Stritch, then Catholic archbishopO of Research Hospital in Memphis, Tennessee, in 1960 and Chicago, whom Thomas had met when the former was a opened its doors in 1962 to serve children in need through bishop in Toledo. Stritch dissuaded him from building a research and medical care. Dr Donald Pinkel, the first shrine, saying there were plenty already.O They subsequently director, initiated the ÔTotal TherapyÕ series of studies of agreed that a children’s hospital for the needy was a better acute lymphoblastic leukaemia (ALL), which subsequently tribute, something like the Shriner’s hospitals in the USA, demonstrated that the disease was curable in a significant where disabled children received free care. Thomas favoured percentage of children. Pioneering studies in childhood locating the hospital in ChicagoR where he got his show cancer and high-quality basic biological research served as business start. Stritch persuaded him that Chicago already key ingredients in creating an environment of scientific had good children’s facilities and that he should find a place excellence and interdisciplinary activity. During its in greater need. StritchP suggested Memphis, Tennessee, 40 years, the institution has grown in scientific stature where he had been a parish priest and, being a practical and programmatic depth, both made possible by the skill of sort, because he was a good friend of a civic leader in its investigators, and by its physical and financial growth.
    [Show full text]
  • More Than Courage
    More than Courage DANA-FARBER CANCER INSTITUTE It takes more than courage to beat cancer ® What does it take to beat cancer? It takes courage, yes, and that is just the beginning. It takes world-class researchers, doctors, and technologically advanced facilities. It takes teams of dedicated professionals who offer compassionate care every day, gathering insight to inform and advance treatments for everyone. It takes focus and determination— people committed to taking the bold steps necessary to advance the cause. It also takes you. Illustrations throughout this publication represent Dana-Farber’s industry-leading science, technology, and patient care. “ I have never accepted the incurability of cancer.” — Sidney Farber, MD Founder, Dana-Farber Cancer Institute Rooted in innovation and leadership, our history remains a powerful source of motivation. The work that began in a small basement laboratory in 1947 in Boston has evolved and grown over time, and it has made Dana-Farber one of the most prestigious cancer centers in the world. Today, Dana-Farber embodies the very essence of our founder’s pioneering vision: one of leadership grounded in a commitment to research and compassion, driven to provide expert care to adults and children with cancer. It takes Experience dana-farber.org | jimmyfund.org 3 Experience Dana-Farber is a global leader in cancer A Revolutionary research and patient care. 396,000+ Vision Patient visits and infusions, annually Dana-Farber founder Sidney Farber, MD, is the father of modern chemotherapy. Founding the Institute in 1947 in Boston, Dr. Farber and his team dedicated their work to providing compassionate, state-of-the-art treatment for cancer patients, 4,500+ while researching cures of the future.
    [Show full text]
  • Sidney Farber, M.D. 1903-1973 658 CANCER RESEARCH VOL. 34
    Si Sidney Farber, M.D. 1903-1973 658 CANCER RESEARCH VOL. 34 Downloaded from cancerres.aacrjournals.org on October 2, 2021. © 1974 American Association for Cancer Research. OBITUARY Sidney Farber, M.D. On the evening of March 30, 1973, Dr. Sidney Farber, tion of transposition of the great vessels, a major contribu President, Director of Research, and Founder (in 1947) tion to the development of pediatrie cardiac surgery; and of The Children's Cancer Research Foundation, Inc., and focused attention on the sudden death syndrome in in S. Burt Wolbach Professor of Pathology, Emeritus, Har fants. vard Medical School, died in his office. In recent years he In 1946, Dr. Farber became Chairman of the Division of had often expressed his hope to me that he might "die in Laboratories and Research, The Children's Hospital and, harness," which he did, having spent more than 2 of the in 1947, was named Pathologist-in-Chief. Harvard Medi last hours of his life with Emil Frei, III, and me discuss cal School appointed him Professor of Pathology in 1948 ing future plans for the Foundation. American medicine and, in 1967, he became the first incumbent of the newly has lost one of its most illustrious figures, and cancer and created S. Burt Wolbach Professorship in Pathology. biomédicalresearch around the world has lost a remark In 1946, The Children's Hospital named him Chairman ably articulate and effective medical statesman and of the Staff Planning Committee; and in 1964, he was spokesman. named Chairman of the Staff, with responsiblity for the Born on September 30, 1903, in Buffalo, N.
    [Show full text]
  • A Legacy of Hope for Young Leukemia Patients
    For more on the Giants of Cancer Care®, visit Giants.OncLive.com Joseph V. Simone, MD An Innovator in Pediatric Cancer Care Joseph V. Simone, MD, is best known for leading the research efforts that resulted in the first curative com- bination treatment for certain pediatric patients with acute lymphoid leukemia. Under his leadership, the St. Jude Children’s Research Hospital in Memphis, Tennessee, was designated the first and only National Cancer Institute cancer center dedicated to children. He was honored in the Pediatric Oncology category with a 2017 Giants of Cancer Care® award. A Legacy of Hope for Young Leukemia Patients BY ANGELICA WELCH IN THE 1960S, PROGRAMS for treating the kids will understand. It’s tricky, though, to find cures for more children. “When you get leukemia were few and far between—especially because you can scare them, the parents are one like that, you get very, very anxious to get for children. The disease was just beginning scared—and sometimes I am scared. But I think more. That pushed us on,” he says. to be understood, and rules and regulations [having] that group—parents, doctor, our superb for taking care of both adult and pediatric nurses, and the patients involved—is something A MENTOR patients were underdeveloped and inefficient, [for which] we do not provide enough training When asked about the great strides made in as the first treatment for systemic cancers had for people,” Simone admits. the 1960s and 1970s for childhood leukemia, been developed only a decade earlier. St. Jude’s prominence grew with Simone’s Simone credits his mentor, Donald Pinkel, MD.
    [Show full text]
  • The Original Documents Are Located in Box 23, Folder “4/4-5/76 - Wisconsin (3)” of the Sheila Weidenfeld Files at the Gerald R
    The original documents are located in Box 23, folder “4/4-5/76 - Wisconsin (3)” of the Sheila Weidenfeld Files at the Gerald R. Ford Presidential Library. Copyright Notice The copyright law of the United States (Title 17, United States Code) governs the making of photocopies or other reproductions of copyrighted material. Gerald Ford donated to the United States of America his copyrights in all of his unpublished writings in National Archives collections. Works prepared by U.S. Government employees as part of their official duties are in the public domain. The copyrights to materials written by other individuals or organizations are presumed to remain with them. If you think any of the information displayed in the PDF is subject to a valid copyright claim, please contact the Gerald R. Ford Presidential Library. ~"":Jl"'. - •;:; r i Digitized from Box 23 of the Sheila Weidenfeld Files at the Gerald R. Ford Presidential Library . ! l ,~ - 6 - Monday, April 5, 1976 9:45 am Mrs. Ford departs Suite en route motorcade .for boarding. Motorcade assignments as on arrival except delete Mr. & Mrs. Coleman from Mrs. Ford's car. 9:50 am MOTORCADE DEPARTS Edgewater Hotel en route Truax Field. [Driving time: 20 minutes] 10:10 am MOTORCADE ARRIVES Truax Field. I"' .. Mrs. Ford boards C-9. ' f Manifest as on arrival, except add f' P. Sorum, P. Matson, & D. Kinley•. Ij l 10:20 am C-9 DEPARTS Truax Field en route General Mitchell i Field, Wlwaukee, Wisconsin. [Flying time: 25 minutes] I' [No time change.) 10:45 am C-9 ARRIVES General Mitchell Field, Milwaukee, Wisconsin (Air National Guard Ramp).
    [Show full text]
  • Introduction of Donald Pinkel
    Introduction of Donald Pinkel F. Lampert Organizers, colleagues, ladies and gentle­ then to do a proper evaluation. As to the men, and above all, dear Don, everything pathogenesis of a disease, you can read is evolution, and every new field in med­ about this everywhere in a book, but the icine has its beginnings and its pioneers. patient is unique!" The story of pediatric oncology is a short The second time I spoke to Don was on but fascinating one, now covering 40 the telephone, calling from Munich to years, a time span considered holy since Memphis. It was on a Tuesday, the 18th biblical times. In Germany, that is, in of May, 1971. The mother of a freshly West Germany or the Federal Republic diagnosed 6-year-old boy with acute of Germany, the real and effective pedi­ lymphoblastic leukemia (ALL) urged me atric oncology has an even shorter histo­ to call Dr. Pinkel. She had just read in ry, and its beginning is closely connected the German news magazine Der Spiegel with Dr. Pinkel's name. It is thus a great about an almost 20% 5-year-cure rate for pleasure and an honor to introduce Don­ ALL achieved by Dr. Pinkel's group at ald Pinkel. St. Jude's Hospital, published in the I could now present to you Don Journal of the American Medical Associ­ Pinkel's scientific career, or when and ation at the end of April. I had my where he was born - I think it must have doubts, but on the phone he told me been 1926, somewhere in the USA - or something about "total therapy," includ­ mention the many awards he received, ing radiation of the central nervous sys­ the last, if I remember correctly, being tem, about aggressive multiagent therapy the most prestigious and substantial up to the biological tolerance of the pa­ Charles Kettering prize from the General tient, and about 300 or more active pa­ Motors Foundation in 1986, but I will tients with ALL currently under treat­ confine myself to some personal memo­ ment at St.
    [Show full text]
  • Mary Lasker Oral History Interview – JFK#1, 04/18/1966 Administrative Information
    Mary Lasker Oral History Interview – JFK#1, 04/18/1966 Administrative Information Creator: Mary Lasker Interviewer: Charles T. Morrissey Date of Interview: April 18, 1966 Place of Interview: New York City, New York Length: 26 pages Biographical Note Mary Lasker was a well-known and successful health activist and philanthropist; co- founder of the Lasker Foundation; founder of the National Health Education Committee; the president of the Birth Control Federation of America; the winner of a Presidential Medal of Freedom (1969) and the Congressional Gold Medal (1989); and a personal acquaintance of John F. Kennedy [JFK] and later, after his death, a close friend of several members of JFK’s family. In this interview Lasker discusses her work lobbying for different health and medical programs such as a presidential commission on strokes; her encounters with JFK, both in the White House and socially; her friendship with Adlai E. Stevenson and his experience during the 1960 presidential campaigns; and her work on the National Cultural Center Board which she suggested be renamed as a memorial for JFK, among other issues. Access Open. Usage Restrictions According to the deed of gift signed May 30, 1990, copyright of these materials has been assigned to the United States Government. Users of these materials are advised to determine the copyright status of any document from which they wish to publish. Copyright The copyright law of the United States (Title 17, United States Code) governs the making of photocopies or other reproductions of copyrighted material. Under certain conditions specified in the law, libraries and archives are authorized to furnish a photocopy or other reproduction.
    [Show full text]